



1 **Synthesis of Diverse Fused Tetracyclic Thiazepine-Chalcone Derivatives by**
 2 **Claisen-Schmidt Condensation Reaction and their Antimicrobial Activity**

3 JAYANTI B. HIRANI^{1,*}, MAYANK K. PANDYA¹ and SURESH B. KORADIYA²

4 ¹B.R.C.C. Laboratory, Department of Chemistry, School of Science, R K University, Rajkot-360020, India

5 ²Department of Chemistry, Shree M. & N. Virani Science College, Rajkot-360005, India

6 *Corresponding author: E-mail: jayant.hirani@yahoo.co.in

(Received: ; Accepted:) AJC-0000

7 To develop antimicrobial agent, a series of thiazepine-chalcones was synthesized by Claisen-Schmidt condensation between the
 8 couplings of aryl ketone in three steps protocol and different aromatic aldehydes under strong base catalyst at room temperature. The
 9 characterization of final products were carried out by IR, ¹H & ¹³C NMR and elemental analysis. The synthesized compounds were also
 10 evaluated for their antibacterial and antifungal activities using specific Gram positive and Gram-negative bacterial strains using cup plate
 11 method.

12 **Keywords: Claisen-Schmidt condensation, Tetracyclic, Thiazepine, Antimicrobial activity.**

INTRODUCTION

13 Chalcones are well known intermediates for synthesizing
 14 various heterocyclic compounds which comprise the aromatic
 15 ketone that forms the central core of many important biological
 16 compounds, which are to have various biological activities such
 17 as antimicrobial [1], anti-inflammatory [2], locomotor [3],
 18 antiplatelet [4], antimalarial [5], anticancer [6], antiviral [7],
 19 antibacterial, antifungal [8], antiproliferative [9], anti-
 20 Alzheimers [10], TACE and MMP inhibitors [11], inhibition
 21 of leukotriene CysLT [12], antihypertensive [13], antimicrobial
 22 [14], antioxidant [15], anticonvulsant [16], etc. To date numerous
 23 works are reported based on the chemistry of chalcones and is
 24 still an attraction among the organic chemists, due to open-
 25 chain model and the feature of skeletal modification to produce
 26 a new class of organic compounds [17].

27 In short, chalcones are an innovative class of compounds
 28 with significant therapeutic potential against various diseases
 29 particularly when it coupled with other macro/microcyclic systems
 30 [18]. One of the important class of derivatives is benzothiazep-
 31 ines, which shown various biological functions when attached
 32 to chalcone precursor [19]. Benzothiazepines are important
 33 structural scaffolds of seven-membered heterocycles and contain

34 sulfur and nitrogen heteroatoms, due to which they possess a
 35 broad spectrum of pharmacological activities [20]. The distinctive
 36 feature of the thiazepine core is that it is active against
 37 different families of targets, making them interesting hetero-
 38 cyclic ring systems [21]. Various active benzothiazepines are
 39 found in current lead discovery process and first molecule of
 40 1,5-benzothiazepine core was found in cardiovascular action
 41 (diltiazem and cletiazem) [22]. Quetiapine, a derivative of
 42 benzothiazepine, is an antipsychotic drug used for the treat-
 43 ment of schizophrenia and bipolar disorder [23,24].

44 The synthesis of new derivatives possessing antibacterial
 45 activity has considerable attention owing to the continued
 46 increase in bacterial resistance [25]. It is reported that benzo-
 47 thiazepine and substituted benzothiazepine-2-one exhibited
 48 strong antibacterial activity along with unsaturated enone systems
 49 [26]. In present communication, we report a reaction of modified
 50 acetophenone with the different aromatic aldehydes to form novel
 51 chalcone scaffolds (7a-j). The structures of the various synthe-
 52 sized compounds were assigned based on IR, ¹H & ¹³C NMR
 53 spectral data and elemental analysis. These compounds were
 54 also screened for their antimicrobial activity against some
 55 Gram-positive and Gram-negative strains to find the best anti-
 56 bacterial and antifungal agents.

EXPERIMENTAL

57 The required chemicals and solvents for the synthesis were
 58 purchased from Merck Ltd. and SD fine chemicals, India. The
 59 agar medium and PDA medium were purchased from HI media
 60 Laboratories Ltd., Mumbai, India. Most of the reactions were
 61 carried out by standard techniques for the exclusion moisture.
 62 The open-end capillary method was used to determine the melting
 63 points of the synthesized derivatives and are uncorrected. Thin
 64 layer chromatography (TLC) was used for reaction monitoring
 65 using ethyl acetate:*n*-hexane as a mobile phase and visualized
 66 in UV light (254 and 365 nm). IR spectra of all compounds were
 67 recorded on a Shimadzu, Japan IR-435 spectrophotometer using
 68 ATR technique. The ¹H NMR (400 MHz) and ¹³C NMR (101
 69 MHz) spectra were recorded on Bruker AVANCE II Spectro-
 70 meter using DMSO-*d*₆ as solvent and TMS as the internal
 71 reference. Mass spectra were recorded on a Jeol-JMSD 300
 72 mass spectrometer at 70eV. Elemental analysis was carried out
 73 by a Perkin-Elmer 2400 CHN analyzer.

74 Synthesis of 11-chlorodibenzo[*b,f*][1,4]thiazepine (2):

75 Dibenzo[*b,f*][1,4]thiazepin-11-ol (0.01 mol) (1) and 60 mL
 76 POCl₃ were taken in a dry round bottom flask. The reaction
 77 mixture was refluxed with constant stirring at 70 °C for about
 78 3 h. After completion of the reaction, it was cooled to room
 79 temperature and poured into crushed ice. The solid separated
 80 was filtered and dried using a vacuum dryer. The dried product
 81 was recrystallized using methanol to afford analytically pure
 82 products. The progress of the reaction was monitored by TLC
 83 using *n*-hexane:ethyl acetate (6:4) as a mobile phase.

84 Synthesis of 1-(4-(dibenzo[*b,f*][1,4]thiazepin-11-ylamino)- 85 phenyl)ethanone (4):

86 11-Chlorodibenzo[*b,f*][1,4]thiazepine
 87 (0.01 mol) (2) was taken in 70 mL of pyridine in two-necked
 88 round bottom flask. 1-(4-Aminophenyl)ethanone (0.015 mol)
 89 (3) was added into the reaction mixture over for 10 min. It
 90 was heated at 116 °C and continuously stirred for 4 h. After
 91 completion of the reaction, it was cooled to 28 °C and poured
 92 onto crushed ice water under stirring conditions. The obtained
 93 solid was filtered, dried in rota vapor to get 1-[4-(dibenzo[*b,f*]-
 94 [1,4]thiazepine-11-ylamino)phenyl]ethanone (4). The comple-
 95 tion of the reaction was monitored by TLC using ethyl acetate:
 96 benzene (7:3) as a mobile phase.


97 Synthesis of 1-(9*H*-4,15-dithia-9,10-diazatribenzo[*b,ef,i*]- 98 heptalen-6-yl)ethanone (5):

99 In a 100 mL round bottom flask,
 100 mixture of 1-(4-(dibenzo[*b,f*][1,4]thiazepin-11-ylamino)phenyl)-
 101 ethanone (0.01 mol) (4) and sulphur (0.02 mol) were charged
 102 in the presence of catalytic amount of iodine. The reaction mixture
 103 was heated in an oil bath at 161 °C with constant stirring for
 104 30 min. After the completion of the reaction, it was poured
 105 into crushed ice and stirred well for 15 min. The solid separated
 106 was filtered and washed with cold water. The product obtained
 107 was dried and recrystallized from methanol. The purity of the
 108 synthesized compound and the extent of completion of reaction
 109 were monitored using TLC with mobile phase ethyl acetate:
 110 *n*-hexane (3:7).

110 Synthesis of 1-(9*H*-4,15-dithia-9,10-diazatribenzo[*b,ef,i*]- 111 heptalen-6-yl)-3-arylprop-2-en-1-one (7a-j):

Intermediate (5) and different substituted aromatic aldehydes (6a-j) (0.01

mol) in methanol (30 mL) were taken in a round-bottom flask with 30 mL 20% NaOH solution. The reaction mixture was stirred for 24-26 h at ambient temperature. After completion of the reaction, the mixture was poured into crushed ice. The separated solid was filtered, dried and recrystallized from ethanol (Scheme-I).



Reaction condition: (a) POCl₃, reflux, 3 h, (b) pyridine, heat 161 °C, 4 h, (c) sulphur, I₂, heat 161 °C, 30 min, (d) 20% NaOH, RT-stirring, 24-26 h

Scheme-I: Synthetic path for the synthesis of title compounds (7a-j)

1-(9*H*-4,15-Dithia-9,10-diazatribenzo[*b,ef,i*]heptalen-6-yl)-3-phenylprop-2-en-1-one (7a): Yield: 69.35%; m.p.: 201 °C; IR (ν_{\max} , cm⁻¹): 3226 (N-H *str.*), 2975 (C-H *str.*), 1641 (C=O *str.*), 1736 (C=C *str.*), 1534, 1452, 1319 (ring skeleton), 1441 (C-H bend.), 1342 (N-H bend.), 1345 (C-N *str.*), 1254 (C-S *str.*); ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 6.949-6.981 (1H, m, Ar-H), 7.011-7.031 (1H, d, Ar-H), 7.125-7.252 (2H, m, Ar-H), 7.357-7.142 (3H, m, Ar-H), 7.462-7.551 (8H, m, Ar-H), 7.853-7.834 (1H, d, =CH), 8.253-8.232 (1H, d, =CH), 9.625 (1H, s, -NH); ¹³C NMR (101 MHz, DMSO-*d*₆) δ ppm: 191.85, 145.51, 144.21, 144.21, 143.22, 140.85, 138.21, 135.84, 133.78, 132.02, 131.95, 130.12, 128.77, 128.77, 127.52, 125.11, 125.11, 124.80, 127.36, 127.36, 125.32, 123.52, 121.02, 117.58, 125.37, 104.95; MS: *m/z* 462 (M⁺); Elemental analysis calcd. (found) % for C₂₈H₁₈N₂O₂S₂: C, 72.70 (72.65); H, 3.92 (3.95); N, 6.06 (6.11); O, 3.46 (3.40); S, 13.86 (13.83).

1-(9*H*-4,15-Dithia-9,10-diazatribenzo[*b,ef,i*]heptalen-6-yl)-3-(2-methoxyphenyl)prop-2-en-1-one (7b): Yield: 71.42%; m.p.: 218 °C; IR (ν_{\max} , cm⁻¹): 3238 (N-H *str.*), 2960 (C-H *str.*), 1648 (C=O *str.*), 1616 (C=C *str.*), 1554, 1440, 1328 (ring skeleton), 1416 (C-H bend.), 1322 (N-H bend.), 1325 (C-N *str.*), 1258 (C-S *str.*), 1152 (C-O *str.*); ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 3.819 (3H, s, -OCH₃), 6.973-7.031 (2H, d, Ar-H), 7.156-7.286 (2H, m, Ar-H), 7.411-7.396 (3H, m, Ar-H), 7.501-7.590 (7H, m, Ar-H), 7.862-7.841 (1H, d, =CH), 8.258-8.239 (1H, d, =CH), 9.632 (1H, s, -NH); ¹³C NMR (101 MHz,

- 144 DMSO-*d*₆) δ ppm: 193.25, 168.21, 154.45, 151.78, 151.78,
145 148.12, 146.08, 140.85, 138.26, 135.80, 134.10, 133.42, 132.90,
146 131.20, 130.42, 128.12, 127.20, 126.85, 123.51, 121.86, 120.12,
147 118.41, 117.20, 115.65, 114.62, 110.51, 46.81; MS: *m/z* 492
148 (M⁺); Elemental analysis calcd. (found) % for C₂₉H₂₀N₂O₂S₂:
149 C, 70.71 (70.74); H, 4.09 (4.06); N, 5.69 (5.72); O, 6.50 (6.48);
150 S, 13.02 (13.05).
- 151 **1-(9H-4,15-Dithia-9,10-diazatribenzo[*b,ef,i*]heptalen-6-**
152 **yl)-3-(4-methoxyphenyl)prop-2-en-1-one (7c):** Yield: 83.01%;
153 m.p.: 215 °C; IR (ν_{max}, cm⁻¹): 3232 (N-H *str.*), 2928 (C-H *str.*),
154 1634 (C=O *str.*), 1665 (C=C *str.*), 1588, 1441, 1324 (ring skeleton),
155 1414 (C-H bend.), 1384 (N-H bend.), 1324 (C-N *str.*), 1253
156 (C-S *str.*), 1178 (C-O *str.*); ¹H NMR (400 MHz, DMSO-*d*₆) δ
157 ppm: 3.736 (3H, s, -OCH₃), 6.854-6.912 (2H, d, Ar-H), 7.041-
158 7.152 (2H, m, Ar-H), 7.378-7.297 (3H, m, Ar-H), 7.497-7.478
159 (7H, m, Ar-H), 7.858-7.836 (1H, d, =CH), 8.241-8.262 (1H,
160 d, =CH), 9.621 (1H, s, -NH); ¹³C NMR (101 MHz, DMSO-*d*₆)
161 δ ppm: 191.12, 176.45, 154.10, 151.35, 150.74, 149.14, 146.82,
162 141.20, 138.23, 135.59, 133.18, 132.20, 130.85, 130.85, 128.23,
163 128.23, 127.23, 125.95, 123.21, 121.85, 120.98, 119.12, 117.86,
164 115.95, 112.23, 111.95, 49.49; MS: *m/z* 492 (M⁺); Elemental
165 analysis calcd. (found) % for C₂₉H₂₀N₂O₂S₂: C, 70.71 (70.68);
166 H, 4.09 (4.11); N, 5.69 (5.64); O, 6.50 (6.56); S, 13.02 (13.07).
- 167 **1-(9H-4,15-Dithia-9,10-diazatribenzo[*b,ef,i*]heptalen-**
168 **6-yl)-3-(3,4-dimethoxyphenyl)prop-2-en-1-one (7d):** Yield:
169 76.69%; m.p.: 234 °C; IR (ν_{max}, cm⁻¹): 3246 (N-H *str.*), 2978
170 (C-H *str.*), 1635 (C=O *str.*), 1627 (C=C *str.*), 1561, 1416, 1394
171 (ring skeleton), 1418 (C-H bend.), 1360 (N-H bend.), 1367
172 (C-N *str.*), 1256 (C-S *str.*), 1132 (C-O *str.*); ¹H NMR (400 MHz,
173 DMSO-*d*₆) δ ppm: 3.839-3.825 (6H, s, -OCH₃), 6.952-6.993
174 (1H, m, Ar-H), 7.021-7.042 (1H, d, Ar-H), 7.146-7.266 (2H,
175 m, Ar-H), 7.369-7.432 (3H, m, Ar-H), 7.483-7.586 (6H, m,
176 Ar-H), 7.856-7.837 (1H, d, =CH), 8.255-8.235 (1H, d, =CH),
177 9.626 (1H, s, -NH); ¹³C NMR (101 MHz, DMSO-*d*₆) δ ppm:
178 195.45, 184.12, 171.56, 162.58, 160.28, 160.28, 156.20, 151.52,
179 148.85, 146.76, 143.89, 140.86, 139.20, 137.81, 138.81, 135.20,
180 132.95, 130.85, 129.85, 127.21, 126.95, 124.45, 122.20, 118.36,
181 116.51, 113.89, 51.23, 51.23; MS: *m/z* 522 (M⁺); Elemental
182 analysis calcd. (found) % for C₃₀H₂₂N₂O₃S₂: C, 68.94 (68.89);
183 H, 4.24 (4.18); N, 5.36 (5.38); O, 9.18 (9.21); S, 12.27 (12.29).
- 184 **1-(9H-4,15-dithia-9,10-diazatribenzo[*b,ef,i*]heptalen-6-**
185 **yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (7e):** Yield:
186 85.75%; m.p.: 249 °C; IR (ν_{max}, cm⁻¹): 3225 (N-H *str.*), 2976
187 (C-H *str.*), 1642 (C=O *str.*), 1640 (C=C *str.*), 1524, 1458, 1328
188 (ring skeleton), 1412 (C-H bend.), 1348 (N-H bend.), 1347
189 (C-N *str.*), 1172 (C-O *str.*); ¹H NMR (400 MHz, DMSO-*d*₆) δ
190 ppm: 3.781 (9H, s, -OCH₃), 6.941-6.972 (1H, m, Ar-H), 7.009-
191 7.021 (1H, d, Ar-H), 7.128-7.249 (2H, m, Ar-H), 7.331-7.406
192 (2H, m, Ar-H), 7.471-7.558 (6H, m, Ar-H), 7.851-7.829 (1H,
193 d, =CH), 8.249-8.228 (1H, d, =CH), 9.626 (1H, s, -NH); ¹³C NMR
194 (101 MHz, DMSO-*d*₆) δ ppm: 194.25, 184.45, 179.58, 175.20,
195 168.10, 165.25, 160.98, 159.14, 156.10, 148.85, 145.85, 144.89,
196 142.98, 139.42, 137.81, 134.74, 134.74, 130.89, 129.10, 127.96,
197 125.12, 124.56, 123.29, 120.85, 103.56, 103.56, 69.12, 48.21,
198 48.21; MS: *m/z* 552 (M⁺); Elemental analysis calcd. (found)
199 % for C₃₁H₂₄N₂O₄S₂: C, 67.37 (67.33); H, 4.38 (4.41); N, 5.07
200 (5.11); O, 11.58 (11.54); S, 11.60 (11.57).
- 1-(9H-4,15-Dithia-9,10-diazatribenzo[*b,ef,i*]heptalen-**
6-yl)-3-(2-nitrophenyl)prop-2-en-1-one (7f): Yield: 77.57%;
m.p.: 252 °C; IR (ν_{max}, cm⁻¹): 3223 (N-H *str.*), 2971 (C-H *str.*),
1649 (C=O *str.*), 1632 (C=C *str.*), 1545 (C-NO₂ *str.*), 1527, 1438,
1317 (ring skeleton), 1403 (C-H bend.), 1346 (N-H bend.),
1324 (C-N *str.*), 1242 (C-S *str.*); ¹H NMR (400 MHz, DMSO-
*d*₆) δ ppm: 6.583-6.610 (2H, m, Ar-H), 6.702-6.786 (2H, m,
Ar-H), 6.965-7.182 (2H, m, Ar-H), 7.226-7.367 (2H, m, Ar-H),
7.471-7.956 (6H, m, Ar-H), 7.846-7.827 (1H, d, =CH), 8.236-
8.217 (1H, d, =CH), 9.635 (1H, s, -NH); ¹³C NMR (101 MHz,
DMSO-*d*₆) δ ppm: 192.12, 178.12, 175.10, 169.45, 166.74,
161.12, 157.89, 155.41, 152.63, 140.86, 138.52, 137.25, 135.81,
134.63, 134.63, 132.85, 131.45, 130.41, 130.41, 129.45, 127.582,
123.09, 120.58, 118.34, 118.34, 109.80; MS: *m/z* 507 (M⁺);
Elemental analysis calcd. (found) % for C₂₈H₁₇N₃O₃S₂: C, 66.26
(66.24); H, 3.38 (3.41); N, 8.28 (8.25); O, 9.46 (9.49); S, 12.63
(12.58).
- 1-(9H-4,15-Dithia-9,10-diazatribenzo[*b,ef,i*]heptalen-**
6-yl)-3-(3-nitrophenyl)prop-2-en-1-one (7g): Yield: 82.63%;
m.p.: 259 °C; IR (ν_{max}, cm⁻¹): 3234 (N-H *str.*), 2978 (C-H *str.*),
1645 (C=O *str.*), 1667 (C=C *str.*), 1584 (C-NO₂ *str.*), 1552, 1458,
1378 (ring skeleton), 1456 (C-H bend.), 1320 (N-H bend.),
1388 (C-N *str.*), 1253 (C-S *str.*); ¹H NMR (400 MHz, DMSO-*d*₆)
δ ppm: 6.612-6.628 (1H, m, Ar-H), 6.755-6.776 (1H, d, Ar-H),
6.821-7.220 (3H, m, Ar-H), 7.301-7.378 (2H, m, Ar-H), 7.568-
7.978 (7H, m, Ar-H), 7.768-7.786 (1H, d, =CH), 8.178-8.20
(1H, d, =CH), 9.618 (1H, s, -NH); ¹³C NMR (101 MHz, DMSO-
*d*₆) δ ppm: 191.12, 188.47, 181.45, 179.12, 179.12, 168.42,
166.52, 160.74, 152.56, 150.45, 147.20, 144.41, 140.245, 136.75,
135.45, 135.45, 133.82, 132.20, 130.89, 128.45, 125.78, 124.23,
123.45, 122.81, 121.81, 107.72; MS: *m/z* 507 (M⁺); Elemental
analysis calcd. (found) % for C₂₈H₁₇N₃O₃S₂: C, 66.26 (66.29);
H, 3.38 (3.44); N, 8.28 (8.30); O, 9.46 (9.41); S, 12.63 (12.67).
- 1-(9H-4,15-dithia-9,10-diazatribenzo[*b,ef,i*]heptalen-**
6-yl)-3-(4-nitrophenyl)prop-2-en-1-one (7h): Yield: 88.68%;
m.p.: 272 °C; IR (ν_{max}, cm⁻¹): 3232 (N-H *str.*), 2951 (C-H *str.*),
1643 (C=O *str.*), 1687 (C=C *str.*), 1582 (C-NO₂ *str.*), 1584, 1444,
1325 (ring skeleton), 1462 (C-H bend.), 1359 (N-H bend.),
1321 (C-N *str.*), 1288 (C-S *str.*); ¹H NMR (400 MHz, DMSO-*d*₆)
δ ppm: 6.948-6.988 (1H, m, Ar-H), 7.017-7.038 (1H, d, Ar-H),
7.149-7.269 (2H, m, Ar-H), 7.355-7.455 (3H, m, Ar-H), 7.438-
7.589 (7H, m, Ar-H), 7.856-7.837 (1H, d, =CH), 8.255-8.235
(1H, d, =CH), 9.631 (1H, s, -NH); ¹³C NMR (101 MHz, DMSO-
*d*₆) δ ppm: 194.12, 182.72, 179.35, 159.63, 159.63, 156.74,
154.85, 153.08, 149.52, 148.58, 146.95, 143.56, 138.42, 136.89,
136.89, 136.89, 134.20, 130.07, 129.31, 129.31, 126.02, 125.98,
123.29, 120.20, 117.95, 104.42; MS: *m/z* 507 (M⁺); Elemental
analysis calcd. (found) % for C₂₈H₁₇N₃O₃S₂: C, 66.26 (66.28);
H, 3.38 (3.39); N, 8.28 (8.23); O, 9.46 (9.41); S, 12.63 (12.60).
- 1-(9H-4,15-dithia-9,10-diazatribenzo[*b,ef,i*]heptalen-6-**
yl)-3-(4-aminophenyl)prop-2-en-1-one (7i): Yield: 72.77%;
m.p.: 193 °C; IR (ν_{max}, cm⁻¹): 3296 (N-H *str.*), 2968 (C-H *str.*),
1643 (C=O *str.*), 1624 (C=C *str.*), 1526, 1445, 1369 (ring
skeleton), 1406 (C-H bend.), 1342 (N-H bend.), 1365 (C-N *str.*),
1254 (C-S *str.*); ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 4.635-
4.218 (2H, s, -NH₂), 6.552-6.638 (1H, m, Ar-H), 7.021-7.266
(3H, m, Ar-H), 7.352-7.524 (4H, m, Ar-H), 7.561-7.769 (6H, 257

258 m, Ar-H), 7.902-7.884 (1H, d, =CH), 8.236-8.254 (1H, d,
259 =CH), 9.632 (1H, s, -NH); ¹³C NMR (101 MHz, DMSO-*d*₆) δ
260 ppm: 191.85, 185.12, 181.85, 175.48, 175.48, 168.15, 165.71,
261 162.02, 159.43, 155.45, 151.32, 148.32, 141.81, 141.81, 135.26,
262 135.26, 131.58, 129.84, 127.52, 125.23, 123.58, 121.22, 120.89,
263 117.47, 102.85, 102.85; MS: *m/z* 477 (M⁺); Elemental analysis
264 calcd. (found) % for C₂₈H₁₉N₃OS₂: C, 70.41 (70.43); H, 4.01
265 (4.06); N, 8.80 (8.78); O, 3.35 (3.39); S, 13.43 (13.47).

266 **1-(9H-4,15-dithia-9,10-diazatribenzo[*b,ef,i*]heptalen-
267 6-yl)-3-(*p*-tolyl)prop-2-en-1-one (7j):** Yield: 73.35%; m.p.:
268 227 °C; IR (ν_{max}, cm⁻¹): 3237 (N-H *str.*), 2969 (C-H *str.*), 1736
269 (C=O *str.*), 1617 (C=C *str.*), 1527, 1436, 1320 (ring skeleton),
270 1411 (C-H bend.), 1385 (N-H bend.), 1358 (C-N *str.*), 1251
271 (C-S *str.*); ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 2.423 (3H, s,
272 -CH₃), 6.732-6.856 (1H, m, Ar-H), 7.023-7.046 (1H, d, Ar-H),
273 7.152-7.278 (2H, m, Ar-H), 7.353-7.478 (3H, m, Ar-H), 7.520-
274 7.706 (7H, m, Ar-H), 7.850-7.832 (1H, d, =CH), 8.252-8.232
275 (1H, d, =CH), 9.626 (1H, s, -NH); ¹³C NMR (101 MHz, DMSO-
276 *d*₆) δ ppm: 193.25, 180.51, 177.69, 177.69, 175.25, 171.29,
277 165.28, 158.14, 156.85, 150.01, 148.21, 137.52, 134.09, 130.22,
278 130.22, 128.98, 128.98, 127.87, 127.56, 126.33, 123.50, 122.41,
279 120.45, 119.87, 118.89, 111.98, 12.31; MS: *m/z* 476 (M⁺);
280 Elemental analysis calcd. (found) % for C₂₉H₂₀N₂OS₂: C, 73.08
281 (73.10); H, 4.23 (4.19); N, 5.88 (5.91); O, 3.36 (3.39); S, 13.46
282 (13.51).

283 **Antimicrobial evaluation:** The synthesized compounds
284 (7a-j) were screened for their antimicrobial activity against
285 two Gram-positive bacteria *viz.*, *Bacillus megaterium*, *Bacillus*
286 *subtilis* and two Gram-negative bacteria *viz.*, *Escherichia coli*,
287 *Enterobacter aerogenes* by using cup plate method [27].
288 Similarly, the compounds were also tested for their antifungal
289 activity using potato-dextrose-agar (PDA) medium by the same
290 cup plate method against *Aspergillus awamori*.

RESULTS AND DISCUSSION

291 Claisen-Schmidt condensation reaction of novel aceto-
292 phenone synthesized using three-step procedures starting with
293 dibenzo[*b,f*][1,4]thiazepin-11-ol in POCl₃ medium followed
294 by chloroamine coupling in pyridine as a base catalyst obtained

295 1-[4-(dibenzo[*b,f*][1,4]thiazepin-11-ylamino)phenyl]ethanone 295
296 in high yield (91%). Intermediate 5 was synthesized by solid-
297 phase synthesis of iodine catalyzed reaction with sulphur in
298 passable heating conditions. Solution-phase synthesis of 1-
299 (9H-4,15-dithia-9,10-diazatribenzo[*b,ef,i*]heptalen-6-yl)-3-
300 arylprop-2-en-1-one (7a-j) was carried out by heating under
301 reflux of intermediate novel acetophenone (5) with various
302 arylaldehydes (6a-j) in dry MeOH in the presence of 20%
303 NaOH solution.

304 The structure of synthesized compounds 7a-j was confir-
305 med on the basis of spectral data. The IR spectrum of comp-
306 ound 7a showed a strong adsorption band at ~3236 cm⁻¹ due
307 to N-H stretching, secondary amine. Absorption band appeared
308 at ~2984 cm⁻¹ due to stretching vibrations of aromatic hydrogen
309 and absorption band at ~1687 cm⁻¹ due to stretching vibration
310 to >C=O group. Sharp absorption peak observed at ~1584 cm⁻¹
311 in -C-NO₂ group. The absorption band at ~1321, ~1253 cm⁻¹
312 corresponding to C-N, C-S stretching, respectively. In ¹H NMR,
313 an appearance of singlet peaks in compounds 7a-j showed a
314 characteristic value at δ = ~9.61 ppm due to the presence of
315 secondary amine group in fused cyclic ring. The presence of
316 =CH- linkage showed a doublet peak at ~8.25 ppm. Three
317 protons of Ar-(OCH₃) displayed singlet at δ = ~3.78 ppm.
318 Remaining all aromatic protons appeared multiplet in the
319 region δ = ~6.49 to ~7.82 ppm. Remaining substituents protons
320 were in good agreement with theoretical values. In ¹³C NMR,
321 the characteristic value around δ = ~175 ppm showed the pres-
322 ence of >C=O group attached with an aromatic ring. The
323 aromatic ring carbon and heterocyclic ring carbons were in
324 decent covenants with the theoretical values. The mass spectrum
325 revealed a molecular ion peak in compounds 7a-j at *m/z* = 462
326 to 552 in mass spectra, molecular ion peak was in agreement
327 with proposed molecular weight and elemental analysis.

328 **Antimicrobial evaluation:** The screening result revealed
329 that compounds 7a-j showed a significant antimicrobial activities.
330 In particular, compound 7c only showed mild inhibitory action
331 on *Bacillus megaterium*. Compounds 7f and 7j also only showed
332 mild inhibitory action on *Bacillus subtilis*. Compound 7d has
333 shown significant activity on *Bacillus megaterium*, *Bacillus*

TABLE-1
in vitro RESULTS OF ANTIBACTERIAL SCREENING OF COMPOUNDS 7a-j

| No. | R | Gram-positive bacteria | | Gram-negative bacteria | | Fungi |
|-----|--|--|--|---------------------------------------|---|--|
| | | <i>Bacillus megaterium</i> ATCC 14581 | <i>Bacillus subtilis</i> ATCC 23857 | <i>Escherichia coli</i> ATCC 25922 | <i>Enterobacter aerogenes</i> ATCC 13048 | <i>Aspergillus awamori</i> ATCC 22342 |
| 7a | H | 18 | 17 | 16 | 20 | 19 |
| 7b | 2-OCH ₃ | 17 | 13 | 20 | 18 | 20 |
| 7c | 4-OCH ₃ | 20 | 16 | 24 | 16 | 18 |
| 7d | 3,4-(OCH ₃) ₂ | 21 | 19 | 21 | 17 | 17 |
| 7e | 3,4,5-(OCH ₃) ₃ | 18 | 14 | 19 | 15 | 22 |
| 7f | 2-NO ₂ | 17 | 18 | 16 | 18 | 23 |
| 7g | 3-NO ₂ | 19 | 14 | 14 | 11 | 13 |
| 7h | 4-NO ₂ | 16 | 12 | 17 | 14 | 11 |
| 7i | 4-NH ₂ | 18 | 15 | 15 | 18 | 14 |
| 7j | 4-CH ₃ | 12 | 18 | 19 | 16 | 18 |
| | Ampicillin | 23 | 18 | 18 | 20 | - |
| | Chloramphenicol | 22 | 20 | 21 | 19 | - |
| | Norfloxacin | 20 | 19 | 22 | 21 | - |
| | Griseofulvin | - | - | - | - | 21 |

334 subtilis and *Escherichia coli*. Compounds **7b**, **7c**, **7d** and **7j**
 335 have shown high potency, especially against *Escherichia coli*.
 336 Compounds **7a**, **7b**, **7f** and **7i** showed mild inhibitory action
 337 on *Enterobacter aerogenes*. All the organisms employed at a
 338 concentration of 50 µg/mL showed considerable antibacterial
 339 and antifungal activities and are comparable to that of standard
 340 drugs.

341 Conclusion

342 In this work, the strategy for the synthesis of desired novel
 343 chalcones indicated that 1-(9*H*-4,15-dithia-9,10-diazatribenzo-
 344 [*b,ef,i*]heptalen-6-yl)-3-arylprop-2-en-1-one derivatives are
 345 pharmacologically moderately potent. The structural modifica-
 346 tions of the basic structure in derived compounds with electron
 347 releasing groups such as methoxy and amine showed better anti-
 348 bacterial activity. Compounds having nitro group exhibited
 349 more antifungal activity. These results suggested that chalcone
 350 derivatives have excellent scope for further development as
 351 commercial antimicrobial agents.

ACKNOWLEDGEMENTS

352 The authors are thankful to NFDD, Saurashtra University,
 353 Rajkot, India for the spectral analysis.

CONFLICT OF INTEREST

354 The authors declare that there is no conflict of interests
 355 regarding the publication of this article.

REFERENCES

1. M. Kumar, K. Sharma, A.K. Fogla, K. Sharma and M. Rathore, *Res. Chem. Intermed.*, **39**, 2555 (2013); <https://doi.org/10.1007/s11164-012-0782-8>
2. Y.H. Kim, J. Kim, H. Park, H.P. Kim, *Biol. Pharm. Bull.*, **30**, 1450 (2007); <https://doi.org/10.1248/bpb.30.1450>
3. J. Higgs, C. Wasowski, A. Marcos, M. Jukic, C.H. Paván, S. Gobec, F. de Tezanos Pinto, N. Colettis and M. Mardera, *Heliyon*, **5**, e01376 (2019); <https://doi.org/10.1016/j.heliyon.2019.e01376>
4. C.-N. Lin, H.-K. Hsieh, H.-H. Ko, M.-F. Hsu, H.-C. Lin, Y.-L. Chang, M.-I. Chung, J.-J. Kang, J.-P. Wang and C.-M. Teng, *Drug Dev. Res.*, **53**, 9 (2001); <https://doi.org/10.1002/ddr.1163>
5. J. Syahri, E. Yuanita, B.A. Nurohmah, R. Armunanto and B. Purwono, *Asian Pac. J. Trop. Biomed.*, **7**, 675 (2017); <https://doi.org/10.1016/j.apjtb.2017.07.004>
6. M.R. Gudisela, N. Srinivasu, C. Mulakayala, P. Bommu, M.B. Rao and N. Mulakayala, *Bioorg. Med. Chem. Lett.*, **27**, 4140 (2017); <https://doi.org/10.1016/j.bmcl.2017.07.029>
7. A.A. El-Emam, M.A. Massoud, E.R. El-Bendary and M.A. El-Sayed, *Bull. Korean Chem. Soc.*, **25**, 991 (2004); <https://doi.org/10.5012/bkcs.2004.25.7.991>
8. V. Ambrogi, G. Grandolini, L. Perioli, M. Ricci, C. Rossi and L. Tuttobello, *Eur. J. Med. Chem.*, **25**, 403 (1990); [https://doi.org/10.1016/0223-5234\(90\)90003-L](https://doi.org/10.1016/0223-5234(90)90003-L)
9. L. Wu, X. Yang, Q. Peng and G. Sun, *Eur. J. Med. Chem.*, **127**, 599 (2017); <https://doi.org/10.1016/j.ejmech.2017.01.021>
10. S. Das, M.A. Laskar, S.D. Sarker, M.D. Choudhury, P.R. Choudhury, A. Mitra, S. Jamil, S.M.A. Lathiff, S.A. Abdullah, N. Basar, L. Nahar and A.D. Talukdar, *Phytochem. Anal.*, **28**, 324 (2017); <https://doi.org/10.1002/pca.2679>
11. A. Zask, J. Kaplan, X. Du, G. MacEwan, V. Sandanayaka, N. Eudy, J. Levin, G. Jin, J. Xu, T. Cummons, D. Barone, S. Ayril-Kaloustian and J. Skotnicki, *Bioorg. Med. Chem. Lett.*, **15**, 1641 (2005); <https://doi.org/10.1016/j.bmcl.2005.01.053>
12. F.C. Cheng, J.J. Feng, K.H. Chen, H. Imanishi, M. Fujishima, H. Takekoshi, Y. Naoki and M. Shimoda, *Phytother. Res.*, **24**, 43 (2010); <https://doi.org/10.1002/ptr.2864>
13. J.W. Skiles, J.T. Suh, B.E. Williams, P.R. Menard, J.N. Barton, B. Loev, H. Jones, E.S. Neiss and A. Schwab, *J. Med. Chem.*, **29**, 784 (1986); <https://doi.org/10.1021/jm00155a032>
14. R. Anisetti and M. Srinivas Reddy, *J. Sulfur Chem.*, **33**, 363 (2012); <https://doi.org/10.1080/17415993.2012.683432>
15. J.A. Diaz, E. Montero, S. Vega, V. Darias, M.L. Tello and S.S. Abdallah, *Arch. Pharm.*, **327**, 157 (1994); <https://doi.org/10.1002/ardp.19943270306>
16. A.L. Banty, *The Antimicrobial Susceptibility Test, Principle and Practice*, edited by Illus lea and Febiger; Philadelphia, USA, pp. 180 (1976).
17. A. Rammohan, J.S. Reddy, G. Sravya, C.N. Rao and G.V. Zyryanov, *Environ. Chem. Lett.*, **18**, 433 (2020); <https://doi.org/10.1007/s10311-019-00959-w>
18. K.M. Kapadiya, K.M. Kavadia, P.A. Manvar and R.C. Khunt, *Antiinfect. Agents*, **13**, 129 (2015); <https://doi.org/10.2174/2211352513666150915235745>
19. K.A. El-Bayouki, *Org. Chem. Int.*, **2013**, 210474 (2013); <https://doi.org/10.1155/2013/210474>
20. A.V. Chate, R.S. Joshi, P.V. Badadhe, S.K. Dabhade and C.H. Gill, *Bull. Korean Chem. Soc.*, **32**, 3887 (2011); <https://doi.org/10.5012/bkcs.2011.32.11.3887>
21. P. Martins, J. Jesus, S. Santos, L.R. Raposo, C. Roma-Rodrigues, P.V. Baptista and A.R. Fernandes, *Molecules*, **20**, 16852 (2015); <https://doi.org/10.3390/molecules200916852>
22. R. Kaur, R. Singh and K. Singh, *Chem. Biol. Lett.*, **3**, 18 (2016).
23. J.R. Scarff and D.A. Casey, *Pharm. Ther.*, **36**, 832 (2011).
24. M. Riedel, N. Müller, M. Strassnig, I. Spellmann, E. Severus and H.J. Möller, *Neuropsychiatr. Dis. Treat.*, **3**, 219 (2007); <https://doi.org/10.2147/ndt.2007.3.2.219>
25. I.E. Cock, M.J. Cheesman, A. Ilanko and B. Blonk, *Pharmacogn. Rev.*, **11**, 57 (2017); https://doi.org/10.4103/phrev.phrev_21_17
26. B.V. Kendre, M.G. Landge and S.R. Bhusare, *Arab. J. Chem.*, **12**, 2091 (2019); <https://doi.org/10.1016/j.arabjc.2015.01.007>
27. H.W. Seeley, P.J. Vandemark and P.J. van Demark, *Microbes in Action: A Laboratory Manual of Microbiology*, W.H. Freeman: New York, edn 4 (1991).